Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Judson

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 8, 2006
Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomasO S Nielsen, P Reichardt, T B Christensen, et al.
Bone Marrow Transplantation|September 11, 1998
The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescueB C Millar, J L Millar, V Shepherd, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2002
A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalationD Fyfe, F Raynaud, R E Langley, et al.
British Journal of Cancer|April 30, 2009
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?S Postel-Vinay, H-T Arkenau, D Olmos, et al.
Lancet (London, England)|January 2, 1982
Co-trimoxazole versus non-absorbable antibiotics in acute leukaemiaJ G Watson, B Jameson, R L Powles, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2008
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma groupM Schlemmer, P Reichardt, J Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2004
A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumoursJ-Y Blay, A Le Cesne, J Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2018
Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database studyA J Verschoor, S Litière, S Marréaud, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2002
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patientsA T van Oosterom, H T Mouridsen, O S Nielsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2011
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignanciesH-T Arkenau, R Plummer, L R Molife, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|August 8, 2006
Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomasO S Nielsen, P Reichardt, T B Christensen, et al.
Bone Marrow Transplantation|September 11, 1998
The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescueB C Millar, J L Millar, V Shepherd, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2002
A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalationD Fyfe, F Raynaud, R E Langley, et al.
British Journal of Cancer|April 30, 2009
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?S Postel-Vinay, H-T Arkenau, D Olmos, et al.
Lancet (London, England)|January 2, 1982
Co-trimoxazole versus non-absorbable antibiotics in acute leukaemiaJ G Watson, B Jameson, R L Powles, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2008
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma groupM Schlemmer, P Reichardt, J Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2004
A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumoursJ-Y Blay, A Le Cesne, J Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2018
Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database studyA J Verschoor, S Litière, S Marréaud, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2002
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patientsA T van Oosterom, H T Mouridsen, O S Nielsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2011
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignanciesH-T Arkenau, R Plummer, L R Molife, et al.
Pageof 12